PriceTargets.com logo

NASDAQ:NVCN - Neovasc Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $125.00
  • Forecasted Upside: 1,494.39 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.84 As of 08/12/2022 01:00 AM ET
▼ -0.09 (-1.13%)

This chart shows the closing price for NVCN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neovasc Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVCN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVCN

Analyst Price Target is $125.00
▲ +1,494.39% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Neovasc in the last 3 months. The average price target is $125.00, with a high forecast of $125.00 and a low forecast of $125.00. The average price target represents a 1,494.39% upside from the last price of $7.84.

This chart shows the closing price for NVCN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Neovasc. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/11/2022HC WainwrightReiterated RatingBuy$125.00High
12/1/2021HC WainwrightReiterated RatingBuy$125.00High
3/14/2021SVB LeerinkReiterated RatingBuy$50.00High
11/6/2020SVB LeerinkLower Price TargetOutperform$150.00 ➝ $50.00High
8/20/2020SVB LeerinkReiterated RatingOutperform ➝ Market Perform$150.00High
7/2/2020HC WainwrightReiterated RatingBuy$125.00N/A
5/8/2020HC WainwrightReiterated RatingBuy$225.00 ➝ $125.00Medium
4/14/2020Noble FinancialInitiated CoverageOutperform$375.00High
11/4/2019HC WainwrightSet Price TargetBuy$225.00Medium
10/24/2019HC WainwrightInitiated CoverageBuy$225.00High
3/29/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$1,250,000.00 ➝ $500,000.00High
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/14/2022
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
2/13/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/15/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/14/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/14/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/13/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/13/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/12/2022

Current Sentiment

  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Neovasc logo
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Read More

Today's Range

Now: $7.84
Low: $7.65
High: $7.90

50 Day Range

MA: $6.30
Low: $4.90
High: $7.93

52 Week Range

Now: $7.84
Low: $4.59
High: $21.56

Volume

16,032 shs

Average Volume

15,823 shs

Market Capitalization

$21.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Neovasc?

The following sell-side analysts have issued reports on Neovasc in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for NVCN.

What is the current price target for Neovasc?

1 Wall Street analysts have set twelve-month price targets for Neovasc in the last year. Their average twelve-month price target is $125.00, suggesting a possible upside of 1,494.4%. HC Wainwright has the highest price target set, predicting NVCN will reach $125.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $125.00 for Neovasc in the next year.
View the latest price targets for NVCN.

What is the current consensus analyst rating for Neovasc?

Neovasc currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVCN will outperform the market and that investors should add to their positions of Neovasc.
View the latest ratings for NVCN.

What other companies compete with Neovasc?

Other companies that are similar to Neovasc include Assure, Nephros, Aethlon Medical, Bluejay Diagnostics and InspireMD. Learn More about companies similar to Neovasc.

How do I contact Neovasc's investor relations team?

Neovasc's physical mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider's listed phone number is (604) 270-4344 and its investor relations email address is [email protected] The official website for Neovasc is www.neovasc.com. Learn More about contacing Neovasc investor relations.